Insight Molecular Diagnostics
IMDX
34 hedge funds and large institutions have $5.64M invested in Insight Molecular Diagnostics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.33% → 0.31% (-0.02%)
19% less funds holding
Funds holding: 42 → 34 (-8)
26% less capital invested
Capital invested by funds: $7.62M → $5.64M (-$1.97M)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$467K |
| 2 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
+$96.7K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$55K |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$31.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$309K |
| 2 |
State Street
Boston,
Massachusetts
|
-$163K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$135K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$111K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$63K |
IMDX Hedge Fund Activity: Q2 2016 in Review
34 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2016, worth a combined $5.64M — down 26% from $7.62M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IMDX and 4 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $467K. The largest seller was BlackRock Fund Advisors, cutting an estimated $309K.
- 34 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2016, down from 42 in Q1 2016.
- Funds reported $5.64M of Insight Molecular Diagnostics stock for Q2 2016, down 26% quarter-over-quarter.
- 4 funds opened new Insight Molecular Diagnostics positions in Q2 2016 and 12 closed out, a net change of -8 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2016 was Bridgeway Capital Management, an estimated $467K added.
- The largest Insight Molecular Diagnostics seller in Q2 2016 was BlackRock Fund Advisors, an estimated $309K sold.
Based on aggregated 13F filings for Q2 2016.